Uveitis refers to inflammation of the uvea, the middle layer of the eyeball, which includes the iris, ciliary body and choroid.
Overall 2,300,000 people suffer uveitis in the US, approximately 1 in 118 or 0.85% or 2.3 million people in USA. 30,000 people go blind because of uveitis in the US.
Eye drops are the first line choice of medication for the treatment of Anterior uveitis. For,Intermediate and Posterior Uveitis an injection to be given into or around the eye, although oral medication, intravenous injection and time-release capsules implanted in the eye may also be used. Immunosuppressive medication may be useful to help reduce the inflammation in patients that are unresponsive to other treatments, although must be used with caution.
The SUN Project is a global effort to establish classification criteria for uveitic syndromes. A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis. A Phase 2 clinical study for patients with Multifocal Choroiditis, Panuveitis or Active Vitritis